Clinical and virological effects of NA inhibitors in pediatric patients with influenza B virus infection (between 4 years and 12 years old):an open-label,randomized study.

Clinical and virological effects of NA inhibitors in pediatric patients with influenza B virus infection (between 4 years and 12 years old):an open-label,randomized study. - Clinical and virological effects of NA inhibitors in pediatric patients with influenza B virus infection (between 4 years and 12 years old):an open-label,randomized study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021060

Enrollment

Registered

2016-02-16

Start date

2016-02-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric patients with influenza B virus infection

Interventions

Oseltamivir Peramivir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients between 4 years and 12 years old. 2) Patients or guardian of the patients from whom obtained voluntary written informd consent. 3) Out patients with febrile symptom. 4) Patient who consulted within 48 hours after onset of fever over 37.5 degrees. 5) Patients who showed positive resut of rapid antigen test of Influenza B

Exclusion criteria

Exclusion criteria: 1)History of hypersensitivity caused by neuraminidase inhibitors. 2)Patients with underlying disease as high risk factors that is likely to affect variation of virus. 3)Patients were deemed inappropriate for the study participants.

Design outcomes

Primary

Measure	Time frame
Time to less than lower limit of quantification of virus titer from the start of drug treatment	—

Secondary

Measure	Time frame
Time to return to normal body temperature (below 37.5 degrees) Time to resolution of flu symptoms Time-weighted change from baseline in the virus titer at day 3 and final observation time The drug sensitivity change for each NA inhibitor *Rate of relapse	—

Countries

Japan

Contacts

Public ContactNobuo Hirotsu

Hirotsu Clinic Internal Medicine, Pediatrics

non-hirotsu@umin.ac.jp044-822-1933

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026